Form 8-K - Current report:
SEC Accession No. 0001193125-25-143202
Filing Date
2025-06-20
Accepted
2025-06-20 07:20:07
Documents
12
Period of Report
2025-06-19
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d45802d8k.htm   iXBRL 8-K 25606
  Complete submission text file 0001193125-25-143202.txt   143492

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA klrs-20250619.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE klrs-20250619_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE klrs-20250619_pre.xml EX-101.PRE 11707
14 EXTRACTED XBRL INSTANCE DOCUMENT d45802d8k_htm.xml XML 3790
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Filer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39409 | Film No.: 251059073
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)